These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7270347)

  • 41. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
    Lecrubier C; Girard P; Noire P; Samama M
    Agents Actions Suppl; 1984; 15():60-7. PubMed ID: 6592946
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of treatment on retinal circulation, platelet aggregation and blood viscosity in insulin-dependent and noninsulin-dependent diabetics.
    Uchimura I
    Bull Tokyo Med Dent Univ; 1983 Mar; 30(1):17-24. PubMed ID: 6339093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The use of ticlid in diabetic retinopathy].
    Rubtsova AL; Ametov AS; Strakhov VV
    Ter Arkh; 1997; 69(10):19-21. PubMed ID: 9471782
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Changes of blood coagulability and effects of the platelet aggregation inhibitor (ticlopidine) in experimental subarachnoid hemorrhage in dogs].
    Toyoda O; Nukui H; Horikoshi S; Mitsuka S; Sasaki H; Tamada J; Miyagi O; Shibasaki T; Ohe C
    Neurol Med Chir (Tokyo); 1985 Oct; 25(10):810-7. PubMed ID: 2417133
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-platelet drugs during chronic hemodialysis: an experience with ticlopidine, the 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c] pyridine.
    Bono F; De Gasperi T; Zanelli P; Menta R; Castiglioni A; Savazzi GM; Cambi V
    Farmaco Prat; 1983 Dec; 38(12):451-5. PubMed ID: 6662220
    [No Abstract]   [Full Text] [Related]  

  • 46. Antiaggregant effect of ticlopidine in atherosclerotic patients.
    Manotti C; Potì R; Megna A; Poli T; Alberani M
    Farmaco Prat; 1982 Oct; 37(10):325-30. PubMed ID: 7140941
    [No Abstract]   [Full Text] [Related]  

  • 47. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
    Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
    Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of platelet inhibition on myocardial ischaemia.
    Fox KM; Jonathan A; Selwyn AP
    Lancet; 1982 Oct; 2(8301):727-30. PubMed ID: 6125808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ticlopidine as an experimental antithrombotic agent.
    Vallée E; Maffrand JP; Bernat A; Delebassée D; Tissinier A
    Agents Actions Suppl; 1984; 15():50-9. PubMed ID: 6592945
    [No Abstract]   [Full Text] [Related]  

  • 50. [Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
    Griffanti-Bartoli F; Altomonte F; Pitton L; Armani U; Piana A
    Arch Maragliano Patol Clin; 1979; 35(2):73-80. PubMed ID: 263724
    [No Abstract]   [Full Text] [Related]  

  • 51. Pathways responsible for platelet hypersensitivity in rats with diabetes. II. Spontaneous diabetes in BB Wistar rats.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):154-8. PubMed ID: 3080539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
    de Gaetano G; Bertelé V
    Arq Bras Cardiol; 1983 Dec; 41(6):425-7. PubMed ID: 6678584
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of ticlopidine and acetylsalicylic acid on generation of prostaglandin I2-like substance in rat arterial tissue.
    Ashida S; Abiko Y
    Thromb Res; 1978 Nov; 13(5):901-8. PubMed ID: 369031
    [No Abstract]   [Full Text] [Related]  

  • 54. [Significance of platelet-thrombin interaction in disseminated intravascular coagulopathy (DIC) (author's transl)].
    Fujimura K; Taketomi Y; Mizuno T; Maehama S; Kuramoto A
    Rinsho Byori; 1980 Jul; 28(7):605-9. PubMed ID: 7463754
    [No Abstract]   [Full Text] [Related]  

  • 55. [The efficacy of "Ticlid" in treatment of diabetic retinopathy].
    Mirkiewicz-Sieradzka B; Kostka-Trabka E; Romanowska B; Zygulska-Mach H; Bieroń K; Szpakowicz U; Orzechowska G
    Klin Oczna; 1995; 97(7-8):244-7. PubMed ID: 8531458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss.
    Hoffmann J; Alt A; Lin J; Lochnit G; Schubert U; Schleicher E; Chavakis T; Brownlee M; Van der Woude FJ; Preissner KT; Hammes HP
    Thromb Haemost; 2006 Apr; 95(4):689-95. PubMed ID: 16601840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
    Picard-Fraire C
    Agents Actions Suppl; 1984; 15():68-75. PubMed ID: 6385655
    [No Abstract]   [Full Text] [Related]  

  • 58. [The influence of tinofedrine on fibrinogen and platelet aggregation in patients with recent cerebral infarction (author's transl)].
    Lechner H; Ott E
    Klin Wochenschr; 1978 Nov; 56(22):1137-8. PubMed ID: 713434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-thrombotic action of ticlopidine, a new platelet aggregation inhibitor.
    Tomikawa M; Ashida S; Kakihata K; Abiko Y
    Thromb Res; 1978 Jun; 12(6):1157-64. PubMed ID: 694822
    [No Abstract]   [Full Text] [Related]  

  • 60. [Diabetic retinopathy and thrombosis: an experimental study (author's transl)].
    Ishibashi T; Tanaka K; Taniguchi Y
    Nippon Ganka Gakkai Zasshi; 1980 Aug; 84(8):878-89. PubMed ID: 7211602
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.